New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|January 6, 2015
CPI-613 in Combination With High Dose ARA-C and Mitoxantrone
Author(s)Bayard L. Powell, MD
Bayard L. Powell, MD, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).
Advertisement
Clinical Pearls
Bayard L. Powell, MD, Section Chief, Hematology & Oncology, Director, Leukemia Service, Wake Forest University, discusses aphase I studythat looked atCPI-613in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).
- It is feasible to add CPI-613 to high dose ARA-C and mitoxantrone. No additional toxicity was observed.
- Approximately 50% of patients responded to this combination.
- Older patients and patients with high-risk cytogenetics typically do not respond well to high dose ARA-C and mitoxantrone. With the addition of CPI-613, the response rate was about the same in these groups compared with the entire population.
Advertisement
Related to this article
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5